Next Article in Journal
Cost-Effectiveness Analysis of Ibrutinib in Patients with Waldenström Macroglobulinemia in Italy
Previous Article in Journal
Healthcare Resource Use in Schizophrenia, EuroSC Findings
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1381544
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Essay

Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry

by
Karolina Badora
1,*,
Aleksandra Caban
1,
Cécile Rémuzat
2,
Claude Dussart
3,4 and
Mondher Toumi
5
1
Creativ-Ceutical Poland, Przemysłowa 12, 30-701 Cracow, Poland
2
Creativ-Ceutical France, Paris, France
3
Laboratoire Parcours Santé Systémique, Université Claude Bernard, Lyon, France
4
Faculté de Médecine Laennec, Université de Lyon, Lyon, France
5
Faculté de Médecine, Laboratoire de Santé, Université de la Méditerranée, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1381544; https://doi.org/10.1080/20016689.2017.1381544
Submission received: 6 June 2017 / Revised: 1 January 2017 / Accepted: 13 September 2017 / Published: 25 September 2017

Abstract

In Poland, two proposed amendments to the reimbursement act are currently in preparation; these are likely to substantially change the pricing and reimbursement landscape for both drugs and medical devices. Proposed changes include: alignment of medical device reimbursement with that of pharmaceuticals; relaxing the strict reimbursement criteria for ultra-orphan drugs; establishment of an additional funding category for vaccines; introduction of compassionate use, and a simplified reimbursement pathway for well-established off-label indications; appreciation of manufacturers’ innovation and research and development efforts by creating a dedicated innovation budget; introduction of a mechanism preventing excessive parallel import; prolonged duration of reimbursement decisions and reimbursement lists; and increased flexibility in defining drug programmes. Both amendments are still at a draft stage and many aspects of the new regulations remain unclear. Nonetheless, the overall direction of some of the changes is already evident and warrants discussion due to their high expected impact on pharmaceutical and device manufacturers. Here we evaluate the main changes proposed to the reimbursement of drugs, vaccines, and medical devices, and examine the impact they are likely to have on market access and pharmaceutical industry in Poland.
Keywords: pricing and reimbursement; reimbursement policy; drug policy; medical devices; pharmaceuticals; Poland pricing and reimbursement; reimbursement policy; drug policy; medical devices; pharmaceuticals; Poland

Share and Cite

MDPI and ACS Style

Badora, K.; Caban, A.; Rémuzat, C.; Dussart, C.; Toumi, M. Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry. J. Mark. Access Health Policy 2017, 5, 1381544. https://doi.org/10.1080/20016689.2017.1381544

AMA Style

Badora K, Caban A, Rémuzat C, Dussart C, Toumi M. Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry. Journal of Market Access & Health Policy. 2017; 5(1):1381544. https://doi.org/10.1080/20016689.2017.1381544

Chicago/Turabian Style

Badora, Karolina, Aleksandra Caban, Cécile Rémuzat, Claude Dussart, and Mondher Toumi. 2017. "Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry" Journal of Market Access & Health Policy 5, no. 1: 1381544. https://doi.org/10.1080/20016689.2017.1381544

APA Style

Badora, K., Caban, A., Rémuzat, C., Dussart, C., & Toumi, M. (2017). Proposed Changes to the Reimbursement of Pharmaceuticals and Medical Devices in Poland and Their Impact on Market Access and the Pharmaceutical Industry. Journal of Market Access & Health Policy, 5(1), 1381544. https://doi.org/10.1080/20016689.2017.1381544

Article Metrics

Back to TopTop